Natixis Advisors LLC Has $2.17 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Natixis Advisors LLC cut its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 10.2% during the second quarter, Holdings Channel reports. The institutional investor owned 31,660 shares of the biopharmaceutical company’s stock after selling 3,592 shares during the quarter. Natixis Advisors LLC’s holdings in Intra-Cellular Therapies were worth $2,168,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ITCI. Vanguard Group Inc. lifted its position in shares of Intra-Cellular Therapies by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 9,225,981 shares of the biopharmaceutical company’s stock worth $638,438,000 after acquiring an additional 131,679 shares during the period. Wasatch Advisors LP lifted its position in Intra-Cellular Therapies by 6.3% in the first quarter. Wasatch Advisors LP now owns 3,854,747 shares of the biopharmaceutical company’s stock worth $266,748,000 after purchasing an additional 227,439 shares during the period. Avoro Capital Advisors LLC boosted its stake in Intra-Cellular Therapies by 9.7% during the first quarter. Avoro Capital Advisors LLC now owns 2,475,000 shares of the biopharmaceutical company’s stock worth $171,270,000 after buying an additional 219,445 shares in the last quarter. Clearbridge Investments LLC increased its holdings in Intra-Cellular Therapies by 12.3% in the 1st quarter. Clearbridge Investments LLC now owns 1,744,551 shares of the biopharmaceutical company’s stock valued at $120,723,000 after buying an additional 191,416 shares during the period. Finally, Norges Bank bought a new stake in Intra-Cellular Therapies in the 4th quarter valued at $85,744,000. 92.33% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Sharon Mates sold 53,013 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $75.65, for a total value of $4,010,433.45. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $80,970,388.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Intra-Cellular Therapies news, Director Nostrand Robert L. Van sold 20,000 shares of the company’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $75.91, for a total transaction of $1,518,200.00. Following the transaction, the director now directly owns 9,690 shares in the company, valued at approximately $735,567.90. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Sharon Mates sold 53,013 shares of Intra-Cellular Therapies stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at approximately $80,970,388.85. The disclosure for this sale can be found here. Insiders have sold 199,778 shares of company stock valued at $14,892,738 over the last three months. 3.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ITCI shares. The Goldman Sachs Group decreased their target price on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. JPMorgan Chase & Co. lifted their price objective on Intra-Cellular Therapies from $79.00 to $81.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Mizuho increased their target price on Intra-Cellular Therapies from $96.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, June 21st. Piper Sandler raised Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $68.00 to $92.00 in a research note on Friday. Finally, Cantor Fitzgerald increased their price objective on Intra-Cellular Therapies from $120.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $96.58.

Intra-Cellular Therapies Stock Performance

Shares of ITCI stock opened at $74.41 on Tuesday. Intra-Cellular Therapies, Inc. has a 52 week low of $45.50 and a 52 week high of $84.89. The stock has a market capitalization of $7.86 billion, a PE ratio of -64.15 and a beta of 1.00. The stock’s fifty day moving average is $75.08 and its 200-day moving average is $71.13.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. The firm had revenue of $161.40 million for the quarter, compared to analyst estimates of $157.74 million. Intra-Cellular Therapies had a negative net margin of 14.93% and a negative return on equity of 11.48%. The company’s revenue was up 45.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.45) EPS. As a group, analysts forecast that Intra-Cellular Therapies, Inc. will post -0.59 earnings per share for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.